Healthcare
Live Price
Offline$3.35
+0.00% today
1Y Change
+70.05%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 253 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Shanghai Junshi Biosciences Co., Ltd. (SHJBF) is a Healthcare stock with a market cap of $40.61B and listed on OTC. The stock last traded around $3.35 and up 70.1% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of +24.9%, EPS growth of +35.4%, a dividend yield of 0.0%. What stands out right now is revenue +24.9%, EPS +35.4%, free cash flow +43.1% with operating margin -30.4% and ROIC -6.5%. Valuation already assumes a fairly strong business story at price/sales 14.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SHJBF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SHJBF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SHJBF Max Drawdown
-29.29%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SHJBF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$4.0B
+176.9% YoY
FY Net Income
-$718.6M
+69.9% YoY
Free Cash Flow
-$1.5B
+29.6% YoY
Revenue Growth
+24.9%
EPS Growth
+35.4%
Gross Margin
78.6%
Net Margin
-24.3%
Income statement
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.4B | 1.9B | 1.5B | 1.5B | 4.0B |
| Gross Profit | 1.8B | 1.4B | 835M | 927M | 2.8B |
| Operating Income | -909M | -1.3B | -2.5B | -2.8B | -593M |
| EBITDA | -599M | -1.0B | -2.2B | -2.4B | -308M |
| Net Income | -852M | -1.3B | -2.3B | -2.4B | -719M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2.6B | 2.5B | 3.8B | 6.0B | 3.5B |
| Total Assets | 12.4B | 10.8B | 11.4B | 12.6B | 11.1B |
| Total Liabilities | 6.2B | 4.8B | 4.0B | 2.8B | 2.7B |
| Shareholder Equity | 6.0B | 5.9B | 7.2B | 9.5B | 8.0B |
| Total Debt | 4.1B | 2.9B | 1.8B | 1.3B | 628M |
| Net Debt | 1.5B | 444M | -2.0B | -4.8B | -2.9B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
642M
+63.8% YoY
Capital Expenditures
886M
-125.0% YoY
Free Cash Flow
1.5B
+29.6% YoY
Key ratios
Gross Margin
78.6%
Operating Margin
-30.4%
Net Margin
-24.3%
ROE
-10.8%
Debt / Equity
1.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.